Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial

Jung Sun Kim; Ik Kyung Jang; Chunyu Fan; Tae Hoon Kim; Jin Sun Kim; Sang Min Park; Eui Young Choi; Sang Hak Lee; Young Guk Ko; Donghoon Choi; Myeong Ki Hong; Yangsoo Jang

doi:10.1016/j.jcin.2009.10.006

Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial

Jung Sun Kim, Ik Kyung Jang, Chunyu Fan, Tae Hoon Kim, Jin Sun Kim, Sang Min Park, Eui Young Choi, Sang Hak Lee, Young Guk Ko, Donghoon Choi, Myeong Ki Hong, Yangsoo Jang

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

102 Citations (Scopus)

Abstract

Objectives: We performed this study to investigate the vascular response in early period after zotarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota) implantation. Background: The ZES has different characteristics, with biocompatible polymer and rapid drug-elution, compared with the first-generation drug-eluting stents (DES). Methods: The ENDEAVOR OCT (Evaluation in 3 Months Duration of Neointimal Coverage after Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective, single-center study evaluating vascular healing patterns with optical coherence tomography (OCT) at 3 months after stent implantation. A total of 31 ZES in 30 patients underwent serial OCT at immediate post-intervention and 3 months. Neointimal growth and malapposition were analyzed at each stent strut of cross-sectional OCT images with 0.5-mm intervals. Results: The incidence of malapposition at post-intervention and 3 months was 6.0% and 0.2%, respectively. However, late acquired malapposition was not detected at 3 months. Of 31 stents, 27 stents (87.1%) were covered completely with neointima, but the remaining 4 stents had 2 (0.8%), 4 (0.9%), 4 (1.2%), and 6 (1.4%) uncovered struts. Overall mean percentage of covered stent struts was 99.9 ± 0.4%. This finding was consistent among groups with acute coronary syndrome and stable angina pectoris (99.9 ± 0.3% vs. 99.9 ± 0.4%, p = 0.92). Intracoronary thrombus was documented in 1 stent (3.2%) among 31 stents. Conclusions: Most of the stent struts were covered with neointima, and late acquired malapposition was not found at 3 months after ZES implantation. Therefore, the current study demonstrated that ZES might have a favorable in vivo vascular response at 3 months after stent implantation. (Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography [ENDEAVOR OCT]; NCT00815139).

Original language	English
Pages (from-to)	1240-1247
Number of pages	8
Journal	JACC: Cardiovascular Interventions
Volume	2
Issue number	12
DOIs	https://doi.org/10.1016/j.jcin.2009.10.006
Publication status	Published - 2009 Dec

Bibliographical note

Funding Information:
The authors thank Dr. Nam Wook Hur at the Medical Research Support Section of Yonsei University for statistical support; Dr. Kenichi Fujii of Hyogo University; and Dr. Hiram G. Bezerra at University Hospital, Case Medical Center for careful review for our manuscript.

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jcin.2009.10.006

Cite this

Kim, J. S., Jang, I. K., Fan, C., Kim, T. H., Kim, J. S., Park, S. M., Choi, E. Y., Lee, S. H., Ko, Y. G., Choi, D., Hong, M. K., & Jang, Y. (2009). Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial. JACC: Cardiovascular Interventions, 2(12), 1240-1247. https://doi.org/10.1016/j.jcin.2009.10.006

@article{a0e9c71800be4041a7ce9b749cdca9b1,

title = "Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial",

abstract = "Objectives: We performed this study to investigate the vascular response in early period after zotarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota) implantation. Background: The ZES has different characteristics, with biocompatible polymer and rapid drug-elution, compared with the first-generation drug-eluting stents (DES). Methods: The ENDEAVOR OCT (Evaluation in 3 Months Duration of Neointimal Coverage after Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective, single-center study evaluating vascular healing patterns with optical coherence tomography (OCT) at 3 months after stent implantation. A total of 31 ZES in 30 patients underwent serial OCT at immediate post-intervention and 3 months. Neointimal growth and malapposition were analyzed at each stent strut of cross-sectional OCT images with 0.5-mm intervals. Results: The incidence of malapposition at post-intervention and 3 months was 6.0% and 0.2%, respectively. However, late acquired malapposition was not detected at 3 months. Of 31 stents, 27 stents (87.1%) were covered completely with neointima, but the remaining 4 stents had 2 (0.8%), 4 (0.9%), 4 (1.2%), and 6 (1.4%) uncovered struts. Overall mean percentage of covered stent struts was 99.9 ± 0.4%. This finding was consistent among groups with acute coronary syndrome and stable angina pectoris (99.9 ± 0.3% vs. 99.9 ± 0.4%, p = 0.92). Intracoronary thrombus was documented in 1 stent (3.2%) among 31 stents. Conclusions: Most of the stent struts were covered with neointima, and late acquired malapposition was not found at 3 months after ZES implantation. Therefore, the current study demonstrated that ZES might have a favorable in vivo vascular response at 3 months after stent implantation. (Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography [ENDEAVOR OCT]; NCT00815139).",

author = "Kim, {Jung Sun} and Jang, {Ik Kyung} and Chunyu Fan and Kim, {Tae Hoon} and Kim, {Jin Sun} and Park, {Sang Min} and Choi, {Eui Young} and Lee, {Sang Hak} and Ko, {Young Guk} and Donghoon Choi and Hong, {Myeong Ki} and Yangsoo Jang",

note = "Funding Information: The authors thank Dr. Nam Wook Hur at the Medical Research Support Section of Yonsei University for statistical support; Dr. Kenichi Fujii of Hyogo University; and Dr. Hiram G. Bezerra at University Hospital, Case Medical Center for careful review for our manuscript. ",

year = "2009",

month = dec,

doi = "10.1016/j.jcin.2009.10.006",

language = "English",

volume = "2",

pages = "1240--1247",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "12",

}

Kim, JS, Jang, IK, Fan, C, Kim, TH, Kim, JS, Park, SM, Choi, EY, Lee, SH, Ko, YG, Choi, D , Hong, MK & Jang, Y 2009, 'Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial', JACC: Cardiovascular Interventions, vol. 2, no. 12, pp. 1240-1247. https://doi.org/10.1016/j.jcin.2009.10.006

TY - JOUR

T1 - Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial

AU - Kim, Jung Sun

AU - Jang, Ik Kyung

AU - Fan, Chunyu

AU - Kim, Tae Hoon

AU - Kim, Jin Sun

AU - Park, Sang Min

AU - Choi, Eui Young

AU - Lee, Sang Hak

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Hong, Myeong Ki

AU - Jang, Yangsoo

N1 - Funding Information: The authors thank Dr. Nam Wook Hur at the Medical Research Support Section of Yonsei University for statistical support; Dr. Kenichi Fujii of Hyogo University; and Dr. Hiram G. Bezerra at University Hospital, Case Medical Center for careful review for our manuscript.

PY - 2009/12

Y1 - 2009/12

N2 - Objectives: We performed this study to investigate the vascular response in early period after zotarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota) implantation. Background: The ZES has different characteristics, with biocompatible polymer and rapid drug-elution, compared with the first-generation drug-eluting stents (DES). Methods: The ENDEAVOR OCT (Evaluation in 3 Months Duration of Neointimal Coverage after Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective, single-center study evaluating vascular healing patterns with optical coherence tomography (OCT) at 3 months after stent implantation. A total of 31 ZES in 30 patients underwent serial OCT at immediate post-intervention and 3 months. Neointimal growth and malapposition were analyzed at each stent strut of cross-sectional OCT images with 0.5-mm intervals. Results: The incidence of malapposition at post-intervention and 3 months was 6.0% and 0.2%, respectively. However, late acquired malapposition was not detected at 3 months. Of 31 stents, 27 stents (87.1%) were covered completely with neointima, but the remaining 4 stents had 2 (0.8%), 4 (0.9%), 4 (1.2%), and 6 (1.4%) uncovered struts. Overall mean percentage of covered stent struts was 99.9 ± 0.4%. This finding was consistent among groups with acute coronary syndrome and stable angina pectoris (99.9 ± 0.3% vs. 99.9 ± 0.4%, p = 0.92). Intracoronary thrombus was documented in 1 stent (3.2%) among 31 stents. Conclusions: Most of the stent struts were covered with neointima, and late acquired malapposition was not found at 3 months after ZES implantation. Therefore, the current study demonstrated that ZES might have a favorable in vivo vascular response at 3 months after stent implantation. (Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography [ENDEAVOR OCT]; NCT00815139).

AB - Objectives: We performed this study to investigate the vascular response in early period after zotarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota) implantation. Background: The ZES has different characteristics, with biocompatible polymer and rapid drug-elution, compared with the first-generation drug-eluting stents (DES). Methods: The ENDEAVOR OCT (Evaluation in 3 Months Duration of Neointimal Coverage after Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective, single-center study evaluating vascular healing patterns with optical coherence tomography (OCT) at 3 months after stent implantation. A total of 31 ZES in 30 patients underwent serial OCT at immediate post-intervention and 3 months. Neointimal growth and malapposition were analyzed at each stent strut of cross-sectional OCT images with 0.5-mm intervals. Results: The incidence of malapposition at post-intervention and 3 months was 6.0% and 0.2%, respectively. However, late acquired malapposition was not detected at 3 months. Of 31 stents, 27 stents (87.1%) were covered completely with neointima, but the remaining 4 stents had 2 (0.8%), 4 (0.9%), 4 (1.2%), and 6 (1.4%) uncovered struts. Overall mean percentage of covered stent struts was 99.9 ± 0.4%. This finding was consistent among groups with acute coronary syndrome and stable angina pectoris (99.9 ± 0.3% vs. 99.9 ± 0.4%, p = 0.92). Intracoronary thrombus was documented in 1 stent (3.2%) among 31 stents. Conclusions: Most of the stent struts were covered with neointima, and late acquired malapposition was not found at 3 months after ZES implantation. Therefore, the current study demonstrated that ZES might have a favorable in vivo vascular response at 3 months after stent implantation. (Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography [ENDEAVOR OCT]; NCT00815139).

UR - http://www.scopus.com/inward/record.url?scp=72149133094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149133094&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2009.10.006

DO - 10.1016/j.jcin.2009.10.006

M3 - Article

C2 - 20129551

AN - SCOPUS:72149133094

SN - 1936-8798

VL - 2

SP - 1240

EP - 1247

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 12

ER -

Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography. The ENDEAVOR OCT Trial

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this